Sandoz’s Polpharma Biologics-partnered Tyruko (natalizumab) biosimilar to Tysabri has begun shipping in Norway following a successful tender bid for the multiple sclerosis treatment, the company has disclosed at the J.P. Morgan Annual Healthcare Conference currently taking place in San Francisco, California.
Launching into a space where “we don’t see any competition in the short to medium term,” Tyruko had been “well...






